Company Description
Entrada Therapeutics, Inc., a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases.
The company’s EEV platform develops products based on oligonucleotide, enzyme, and antibody-conjugated EEV peptides.
Its therapeutic candidates, which include ENTR-601-44 that is in Phase 1 clinical trial for the treatment of Duchenne muscular dystrophy; and VX-670, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1.
The company also offers ENTR-601-45, ENTR-601-50, and ENTR-601-51, which are in preclinical trial, for the treatment of Duchenne muscular dystrophy; and PTI-501, an intracellular thymidine phosphorylase enzyme replacement therapy for the treatment of mitochondrial neurogastrointestinal encephalomyopathy.
It has strategic collaboration and license agreements with Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize VX-670; and Pierrepont Therapeutics, Inc. to advance the development of PTI-501.
The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017.
Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.
| Country | United States |
| Founded | 2016 |
| IPO Date | Oct 29, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 183 |
| CEO | Dipal Doshi |
Contact Details
Address: One Design Center Place, Suite 17- 500 Boston, Massachusetts 02210 United States | |
| Phone | 857 520 9158 |
| Website | entradatx.com |
Stock Details
| Ticker Symbol | TRDA |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $20.00 |
| CIK Code | 0001689375 |
| CUSIP Number | 29384C108 |
| ISIN Number | US29384C1080 |
| Employer ID | 81-3983399 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dipal Doshi | Chief Executive Officer and Director |
| Nathan J. Dowden | President and Chief Operating Officer |
| Dr. Natarajan Sethuraman Ph.D. | President of Research and Development |
| Kory James Wentworth CPA | Chief Financial Officer and Treasurer |
| Dr. Jared Cohen J.D., Ph.D. | General Counsel |
| Kerry Robert M.S. | Senior Vice President of People |
| Karla MacDonald | Chief Corporate Affairs Officer |
| Kevin Healy Ph.D. | Senior Vice President of Regulatory Affairs |
| Sandeep Basnet | Head of Information Technology |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 9, 2025 | 144 | Filing |
| Jul 9, 2025 | 144 | Filing |
| Jul 1, 2025 | 144 | Filing |
| Jul 1, 2025 | 144 | Filing |
| Jun 30, 2025 | 144 | Filing |
| Jun 30, 2025 | 144 | Filing |
| Jun 27, 2025 | 144 | Filing |
| Jun 27, 2025 | 144 | Filing |
| Jun 11, 2025 | 8-K | Current Report |
| Jun 3, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |